See the DrugPatentWatch profile for tresiba
Is Tresiba going generic?
Tresiba (insulin degludec) is a branded insulin product. Whether a generic version exists depends on the specific country’s approval status and the drug’s patent and exclusivity timeline.
How to check when generic Tresiba could launch
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, which is one way to estimate when generic manufacturers may be able to enter. You can check Tresiba coverage there, including links to relevant patent records and timelines. [1]
What “generic Tresiba” means for insulin
For insulin medicines, “generic” may be less straightforward than for many small-molecule drugs. Regulators may approve:
- a biosimilar (for insulin products, depending on jurisdiction), or
- an interchangeable product (where that designation exists),
rather than a traditional identical chemical generic.
If there isn’t a generic yet, what alternatives do patients use?
When generic/biosimilar access isn’t available in a given market, patients and clinicians typically rely on:
- the branded product (Tresiba), or
- an approved alternative insulin (sometimes another basal insulin with different prescribing requirements and dosing guidance).
Where to verify current availability
Availability changes by country and by payer formularies. The fastest way to confirm whether a biosimilar or generic basal insulin has been approved and launched where you live is to check local drug approval databases and pharmacy listings, using the patent/exclusivity lead time from resources like DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/